AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00519584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% saline; systemic and local
Study NCT02728284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiovascular MRI (CMR)
Description: CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients
Study NCT02728284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cardiologic Evaluation
Description: ECG (gating), and respiratory motion effects
Study NCT01400724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic NRT
Description: Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
Study NCT03061188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02728076 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase II - Preoperative Radiation followed by Lumpectomy.
Description: Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
Study NCT03816358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV
Study NCT03816358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT03816358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT03816358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03816358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03816358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03061188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03061188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03061188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT04351880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Meals
Description: Compare 2 and 4 weeks of meal delivery
Study NCT01541072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
Study NCT01541072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils >= 0.5 G/L)
Study NCT02091401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Springfusor infusion pump
Study NCT02091401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV administration
Study NCT02091401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Study NCT02091401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Study NCT01509612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Additive classical homeopathy
Description: Homeopathic remedies every 2 to 3 months
Study NCT01509612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Homeopathic Placebo globules
Description: Homeopathic placebo globules every 2 to 3 months
Study NCT01940640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
Study NCT01940640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
Study NCT02587195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Study NCT02895191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Patients will receive the study drugs for 7 to 14 days
Study NCT02895191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive the placebo for 7 to 14 days
Study NCT02595385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell Salvage
Description: Reinfusion of shed blood during the operation
Study NCT02595385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Autologous Prime
Description: Removal of fluid from the bypass circuit
Study NCT03915483 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex
Study NCT03915483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex
Study NCT03141515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
Study NCT03141515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
Study NCT01758614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bypass surgery
Description: all participants in this group will be performed EC-IC bypass surgery
Study NCT01758614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
Study NCT01758614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02378974 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cordstem-ST
Study NCT02378974 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Study NCT04397549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical erector spinae plane block
Description: Cervical erector spinae plane block will be administered before the surgery
Study NCT04397549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study NCT04397549 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study NCT03474445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Plate Osteosynthesis Aptus 2.5
Description: Volar plating of distal radius fracture. Device: Aptus 2.5
Study NCT03474445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Plate Osteosynthesis Inteos 2.5
Description: Volar plating of distal radius fracture. Device: Inteos 2.5
Study NCT00973284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk VLP vaccine
Description: Norwalk VLP vaccine dry powder
Study NCT00973284 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: mannitol and sucrose
Description: Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
Study NCT00973284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk virus
Description: Norwalk virus solution
Study NCT00973284 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Norwalk virus
Description: Norwalk virus solution
Study NCT03569826 — intervention group
Intervention type: OTHER
Intervention: Observational; no intervention
Description: Observational; no intervention
Study NCT04204304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: ISO
Study NCT04204304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: ISO
Study NCT00299403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right prefrontal lowfrequency ( 1 hz) rTMS.
Description: Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2
Study NCT00299403 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: 9 ECT ( 3 each week) during 3 weeks
Study NCT02334345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evoskin
Description: Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
Study NCT02334345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trixiera
Description: Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
Study NCT03023267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy and Kangaroo care
Description: Mother holding baby in skin to skin position while singing
Study NCT03023267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Care alone
Description: Mother holding baby in skin to skin position without singing
Study NCT02595112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus carriage
Description: Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
Study NCT01223937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Study NCT01223937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00835835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training +/- Lokomat assistance
Description: walking
Study NCT00835835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care - no active intervention
Description: No treatment used for comparison
Study NCT01027377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Single dose
Study NCT04504565 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2
Description: intravenous injection of 0.3 mCi/kg of 99mTc-3PRGD2
Study NCT03360214 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride
Description: For active drug, 0.25% marcaine, will be used.
Study NCT03360214 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Drug
Description: For sham drug, 0.9% saline, will be used.
Study NCT03360214 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed Electromagnetic Field (PEMF) Device
Description: The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.
Study NCT03360214 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Device
Description: Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.
Study NCT03360214 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine Hydrochloride
Description: For active drug, 0.25% naropin, will be used.
Study NCT00110357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + Irinotecan
Description: Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
Study NCT00110357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + Irinotecan
Description: Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
Study NCT01748019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST1968
Description: ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
Study NCT00060606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prenatal Myelomeningocele Repair Surgery
Description: Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
Study NCT00060606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postnatal Myelomeningocele Repair Surgery
Description: Standard postnatal surgical closure of the spina bifida defect
Study NCT03739424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole egg powder
Description: Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
Study NCT03739424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole milk powder
Description: Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
Study NCT03739424 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin food product
Description: Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
Study NCT01960166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Distraction
Description: iPad will be used as active distraction
Study NCT01960166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive Distraction
Description: child will watch TV as passive distraction
Study NCT02017093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Error Enhancement
Description: Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
Study NCT02017093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control treatment
Description: Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
Study NCT03155347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
Study NCT03155347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
Study NCT03155347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Participants will receive MTX stable doses at 10 to 25 mg orally.
Study NCT03155347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants will receive MTX stable doses at 10 to 25 mg orally.
Study NCT03155347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matched to MTX
Description: Placebo matched to MTX.
Study NCT03155347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Matched to Tocilizumab
Description: Placebo matched to tocilizumab.
Study NCT02837302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livact
Description: Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
Study NCT00124722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Zemuron)
Description: A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
Study NCT00124722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide (Zemuron)
Description: A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
Study NCT00124722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Zemuron)
Description: A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
Study NCT03883477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Release
Description: Retrograde endoscopic release of the A1 pulley for treatment of trigger finger will be performed using a commercially available device by A.M. Surgical, Inc. This device has been cleared for marketing, sale and use by the U.S. Food and Drug Administration (FDA) for use as an Orthopedic manual surgical instrument based on its similarity in structure and function to previously used devices.
Study NCT03883477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Open Release
Description: Standard open surgical release of the A1 pulley for treatment of trigger finger.
Study NCT03386188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.
Study NCT03386188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Muscle Activity (EMG)
Description: Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
Study NCT00543673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk based formula A
Description: feed as per HCP directions
Study NCT00543673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: #2 Standard formula
Description: Feed as per HCP directions
Study NCT00543673 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: #3 Human Milk
Description: Feed as per HCP directions
Study NCT00543673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk based formula C
Description: Feed as per HCP direction
Study NCT02069106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega LDL
Study NCT02069106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01256099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia
Description: An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
Study NCT01256099 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Internet-CBT for insomnia, without support
Description: No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
Study NCT01256099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist Guided Internet-CBT for depression
Description: An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed